At some point during ketamine therapy, most patients ask the same question: Is this actually working? It’s a fair thing to want to know.
Progress in ketamine therapy for depression isn’t left to intuition. Clinicians use a structured, ongoing evaluation process to measure how you’re responding and adjust your care accordingly.
This article walks through what that process looks like, from the first appointment through long-term maintenance.
Quick Answer Summary
Clinicians track progress during ketamine therapy using a combination of baseline assessments, session-by-session monitoring, and standardized rating scales like the PHQ-9 and MADRS. They also evaluate real-world functional improvements such as sleep, work performance, and relationships. Patient feedback plays a key role in shaping treatment adjustments, including dosing, frequency, and integration with psychotherapy. Ongoing monitoring ensures that initial improvements are sustained and helps prevent relapse through personalized maintenance plans.
Establishing a Baseline
Before any meaningful comparison can happen, a clinician needs to know where you started. The initial assessment in a serious ketamine treatment program covers your full psychiatric and medical history, a review of prior treatments, and standardized symptom scales. Clinicians also document how depression is affecting your day-to-day life, such as your sleep, ability to work, relationships, and daily activities.
That information becomes the reference point for everything that follows. A score drop at a mid-series check-in only tells a real story when it’s measured against something concrete.
Session-by-Session Tracking
Every infusion is a data point. Before each session, a clinician typically asks about your current mood, sleep quality, energy levels, and any side effects that you noticed since your last visit. These pre-session check-ins give the care team a real-time read on how you’re doing between treatments.
After the infusion, the focus shifts. Providers note your immediate response: how you tolerated the session, whether dissociation occurred, and any early mood shifts you can describe. Those post-session observations can surface things that standardized scales miss.
Taken together, these touchpoints build a picture session by session. But individual sessions only tell part of the story. The larger pattern, whether you’re trending toward meaningful response or leveling off, becomes clearer as scores are tracked over weeks, not just hours.
Standardized Rating Scales
This is where clinical monitoring gets precise. Most providers tracking ketamine infusion therapy outcomes use validated scales:
- PHQ-9 for depression
- MADRS (Montgomery-Åsberg Depression Rating Scale) for clinician-rated severity
- GAD-7 when anxiety is part of the picture
Patients complete these at set intervals, before induction, mid-series, and post-treatment, so scores can be compared over time.
The benchmarks matter. In the ELEKT-D trial, response was primarily defined as at least a 50% drop on the QIDS-SR-16, while MADRS remission was defined as a score of 10 or lower. Those thresholds help clinicians interpret whether change is meaningful, even though clinics may not use them in exactly the same way.
A pooled analysis of two Phase 3 studies found that a clinically meaningful improvement corresponded to about a 3-point drop on the PHQ-9 and a 6-point drop on the MADRS, while larger changes signaled more substantial improvement.
A patient whose PHQ-9 score falls from 20 to 13 hasn’t reached remission, but has crossed a real clinical threshold. That distinction informs what happens next.
Tracking Functional Improvement
Symptom scores capture a lot, but they don’t capture everything. A PHQ-9 might still show moderate scores while someone is sleeping consistently, back at work, and reconnecting with people they’d been pushing away. Those changes in daily function matter just as much as what the rating scale says.
Throughout ketamine therapy, clinicians ask structured questions about quality of life at regular intervals:
- Are you returning to activities you’d given up?
- How are your relationships?
- Can you concentrate at work?
These questions are targeted probes into the real-world outcomes that define whether treatment is working.
A VA Health System study of 215 patients with treatment-resistant depression found that those who achieved clinical response by week six maintained those gains at both 12 and 26 weeks, while infusion frequency gradually decreased. That durability only holds when monitoring continues and when the care team is paying attention to both scores and function.
The Patient’s Voice
Your observations belong in the clinical record. The patient’s lived experience is a form of data, and good providers treat it that way.
Journaling between sessions, such as about your mood, sleep, or moments of clarity or heaviness, gives your care team information that structured scales can’t fully capture. Mood-tracking apps do the same. If something shifted after a particular infusion, even briefly, that detail is worth bringing to the next check-in.
You don’t need a formal system. Showing up with specific, honest observations, like “I felt a real lift for about five days after session three, then it faded,” is exactly the kind of input that shapes more personalized care. Clinicians can’t track what they don’t know about.
Adjusting the Plan Based on Your Response
Tracking only has clinical value if someone acts on it. The purpose of all this monitoring is to enable informed, responsive adjustments.
A large retrospective analysis by McInnes et al. covering 9,016 patients across 178 U.S. community practices found that 53.6% of those who completed induction showed clinical response, defined as a 50% or greater PHQ-9 reduction, within 14 to 31 days. Remission was harder to achieve, with 28.9% reaching that threshold. Response rates held consistent across depression severity levels, which means severity alone doesn’t predict who will respond.
That variation in outcomes is exactly why adjustments happen. Some patients improve quickly and hold their gains. Others plateau or experience partial improvement that stalls. Common adjustments include spacing ketamine treatment sessions differently, optimizing the dose, or integrating psychotherapy to extend the therapeutic window.
Maintenance and Sustained Progress
Most patients assume the hardest part is the infusion series. In some ways, what comes after is just as demanding. The question shifts from “is it working?” to “how do we keep it working?”
A systematic review of 11 studies found relapse rates of 27.3% with consistent maintenance schedules versus 45.6% when dosing was irregular. That’s not a small gap. It reflects the gap between regular maintenance schedules and variable dosing patterns.
Months in, the signals can be quiet: sleeping a little worse, withdrawing slightly, and energy dipping before it crashes. Catching those early matters. That’s when a booster makes sense, before the slide becomes a setback. Acute response opens a door. Sustained remission is what ketamine infusion therapy is designed to help you achieve.
The Story Your Symptoms Tell: Co-Authoring Your Recovery
Recovery from depression isn’t linear, and tracking it shouldn’t pretend otherwise. The combination of rating scales, functional check-ins, and your own observations builds something a single score never could: a real portrait of how you’re doing and where care needs to go next.
That’s the difference between treatment that reacts to you and treatment that just follows a script.
At Zeam, your progress shapes your care. We track symptoms, adjust your ketamine therapy for depression as your response changes, and stay involved long after the first series ends. If you live in Sacramento, Folsom, or Roseville, and if that kind of ongoing attention matters to you, reach out today to schedule a consultation.
Key Takeaways
- Treatment starts with a structured baseline – Clinicians establish a starting point by evaluating psychiatric history, prior treatments, and symptom severity using standardized scales before beginning ketamine therapy.
- Each session provides valuable data – Pre- and post-infusion check-ins help clinicians track mood, side effects, and immediate responses, building a session-by-session understanding of progress.
- Standardized scales guide clinical decisions – Tools like the PHQ-9, MADRS, and GAD-7 allow providers to measure meaningful changes in depression and anxiety symptoms over time and determine response or remission.¹
- Functional improvement is just as important as scores – Clinicians assess real-world outcomes such as sleep, work performance, and relationships, which often reflect recovery more accurately than symptom scales alone.
- Patient feedback is a critical part of monitoring – Patient-reported experiences, including mood shifts and journaling insights, provide essential data that helps personalize treatment and guide adjustments.
- Treatment plans evolve based on response – Research shows that while many patients respond to ketamine therapy, outcomes vary, making it essential to adjust dosing, frequency, and complementary therapies over time.⁴
- Maintenance and consistency impact long-term outcomes – Consistent follow-up and maintenance dosing significantly reduce relapse risk and help sustain improvements after the initial treatment phase.⁵
Citations
- ELEKT-D Trial. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302399 - Pooled analysis of Phase 3 ketamine/esketamine studies on depression outcomes.
https://www.sciencedirect.com/science/article/pii/S0165032720329967 - Clinical outcomes of intravenous ketamine in the VA health system.
https://www.psychiatrist.com/jcp/clinical-outcomes-intravenous-ketamine-for-depression-va-health-system/ - McInnes et al. Real-world effectiveness of ketamine therapy across U.S. practices.
https://www.sciencedirect.com/science/article/pii/S0165032721014142 - Systematic review on relapse rates and maintenance strategies in ketamine therapy.
https://www.sciencedirect.com/science/article/abs/pii/S0165032725019172
